Contraception modes: increasing women’s commitment to modern combined oral contraceptives with the shortest possible hormone-free interval

Cover Page


By definition, contraception is the prevention of pregnancy and infection from diseases by mechanical, chemical and other contraceptives and methods. According to World Health Organization (WHO) statistics, up to 40% of women of reproductive age still believe that their needs for family planning services are not met during counseling. When recommending contraception, it is important to consider: the characteristics of the potential consumer, the underlying risk of the disease, possible undesirable drug reactions of various drugs, the cost, availability and preferences of the woman herself. Women are often forced to abandon the use of a contraceptive method in connection with adverse events, for example, when using combined oral contraceptives (COCs), they may feel worse (headaches, mood lability, weight gain, swelling, decreased libido) in a hormone-free interval, especially with the reception mode 21/7. Lack of contraception can lead to an increased risk of an unwanted pregnancy. According to statistics in the Russian Federation in 2018, the absolute number of abortions amounted to 567 183, which, according to the UN classification, corresponds to the average level (level of abortion rate per 1000 women of childbearing age). According to clinical practice, there is a relationship between deterioration of well-being and the duration of the hormone-free interval. At the moment, in our country there is the only COC, which has a hormone-free interval of 2 days, containing bioidentical estrogen – estradiol valerate and dienogest. According to the Cochrane Library, COCs with a short hormone-free interval are most effective in relation to the clinical manifestations of the “estrogen withdrawal” syndrome. WHO calls on clinicians to raise women’s awareness of modern methods of contraception.

Full Text

Restricted Access

About the authors

Elena N. Andreeva

Endocrinology Research Centre; Yevdokimov Moscow State University of Medicine and Dentistry

Author for correspondence.
ORCID iD: 0000-0001-8425-0020
SPIN-code: 1239-2937

Russian Federation, Moscow

D. Sci. (Med.), Prof.

Ekaterina V. Sheremetyeva

Endocrinology Research Centre

ORCID iD: 0000-0001-7177-0254
SPIN-code: 9413-5136

Russian Federation, Moscow

Cand. Sci. (Med.)


  1. Свод практических рекомендаций по применению средств контрацепции. 2-е изд. ВОЗ, Фонд ООН в области народонаселения, 2005. [Selected practice recommendations for contraceptive use. 2nd ed., World Health Organization, 2005. (in Russian).]
  2. Пекинская рабочая программа, 1995 г., п. 95. [Pekinskaia rabochaia programma, 1995 g., p. 95. (in Russian).]
  3. Денисов Б.П., Сакевич В.И. Применение контрацепции в России: по материалам выборочного обследования. Доказательная медицина и клиническая эпидемиология. 2009; 1. [Denisov B.P., Sakevich V.I. Primenenie kontratseptsii v Rossii: po materialam vyborochnogo obsledovaniia. Dokazatel’naia meditsina i klinicheskaia epidemiologiia. 2009; 1. (in Russian).]
  4. Александрова Г.А., Голубев Н.А., Тюрина Е.М. и др. Основные показатели здоровья матери и ребенка, деятельность службы охраны детства и родовспоможения в Российской Федерации. Сборник. М., 2019. [Aleksandrova G.A., Golubev N.A., Tiurina E.M., et al. Osnovnye pokazateli zdorov’ia materi i rebenka, deiatel’nost’ sluzhby okhrany detstva i rodovspomozheniia v Rossiiskoi Federatsii. Sbornik. M., 2019. (in Russian).]
  5. Токова З.З., Прилепская В.Н., Гата А.С., Куземин А.А. Статистика современных методов контрацепции в федеральных округах России. Гинекология. 2016; 18 (4): 68–71. [Tokova Z.Z., Prilepskaya V.N., Gata A.S., Kuzemin A.A. Special statistics of the modern methods of contraception in the federal districs of Russian Federation. Gynecology. 2016; 18 (4): 68–71. (in Russian).]
  6. Egarter C, Frey Tirri B, Bitzer J et al. Women’s perceptions and reasons for choosing the pill, patch, or ring in the CHOICE study: a cross-sectional survey of contraceptive method selection after counseling. BMC Womens Health 2013; 13: 9. doi: 10.1186/1472-6874-13-9
  7. Alkema L, Kantorova V, Menozzi C, Biddlecom A. National, regional, and global rates and trends in contraceptive prevalence and unmet need for family planning between 1990 and 2015: a systematic and comprehensive analysis. Lancet 2013; 381: 1642-52. doi: 10.1016/S0140-6736(12)62204-1
  9. Медицинские критерии приемлемости для использования методов контрацепции. 5-е изд. Женева, ВОЗ, 2015. [Medical eligibility criteria for contraceptive use. 5th ed. Geneva: World Health Organization; 2015 (in Russian).]
  10. Приказ Министерства здравоохранения РФ от 1 ноября 2012 г. №572н «Об утверждении Порядка оказания медицинской помощи по профилю “акушерство и гинекология (за исключением использования вспомогательных репродуктивных технологий)”» [Prikaz Ministerstva zdravookhraneniia RF ot 1 noiabria 2012 g. №572n «Ob utverzhdenii Poriadka okazaniia meditsinskoi pomoshchi po profiliu “akusherstvo i ginekologiia (za iskliucheniem ispol’zovaniia vspomogatel’nykh reproduktivnykh tekhnologii)” (in Russian).]
  11. Дикке Г.Б., Ерофеева Л.В. Контрацепция в современной России: применение и информированность. Популяционное исследование. Акушерство и гинекология. 2016; 2: 108–13. [Dikke G.B., Erofeeva L.V. Kontratseptsiia v sovremennoi Rossii: primenenie i informirovannost’. Populiatsionnoe issledovanie. Akusherstvo i ginekologiia. 2016; 2: 108–13. (in Russian).]
  12. Прилепская В.Н. Руководство по контрацепции. 4-изд., доп. М.: МЕДпресс-информ, 2017. [Prilepskaia V.N. Rukovodstvo po kontratseptsii. 4-izd., dop. M.: MEDpress-inform, 2017 (in Russian).]
  13. MacGregor EA, Guillebaud J. The 7-day contraceptive hormone-free interval should be consigned to history. BMJ Sexual & Reproductive Health 2018. doi: 10.1136/bmjsrh-2017-200036
  14. Dinger J. Comparative effectiveness of combined oral contraceptives in adolescents. J Fam Plann Reprod Health Care 2011; 37: 118. doi: 10.1136/jfprhc.2011.0092
  15. Smith SK, Kirkman RJ, Arce BB et al. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis. Contraception 1986; 34: 513–22. doi: 10.1016/0010-7824(86)90060-0
  16. Zapata LB, Steenland MW, Brahmi D et al. Effect of missed combined hormonal contraceptives on contraceptive effectiveness: a systematic review. Contraception 2013; 87: 685–700. doi: 10.1016/j.contraception.2012.08.035
  17. Baerwald A, Olatunbosun O, Pierson R. Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use. Contraception 2004; 70: 371–7. doi: 10.1016/j.contraception.2004.05.006
  18. Dusterberg B, Nishino Y. Pharmacokinetic and pharmacological features of oestradiol valerate. Maturitas 1982; 4: 315–24. 3.
  19. Smith JD, Oakley D. Why do women miss oral contraceptive pills? An analysis of women’s self-described reasons for missed pills. J Midwifery Women’s Health 2005; 50: 380–5. doi: 10.1016/j.jmwh.2005.01.011
  20. Sulak PJ, Scow RD, Preece C et al. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000; 95: 261–6. doi: 10.1016/s0029-7844(99)00524-4
  21. Archer DF. Menstrual-cycle-related symptoms: a review of the rationale for continuous use of oral contraceptives. Contraception 2006; 74: 359–66. doi: 10.1016/j.contraception.2006.06.003
  22. Nappi RE, Lobo Abascal P, Hsieh J, Micheletti MC. Cycle control with an extended-regimen oral contraceptive combining levonorgestrel and ethinyl estradiol that includes continuous low-dose ethinyl estradiol instead of the traditional hormone-free interval. Int J Womens Health 2017; 9: 739–47. doi: 10.2147/IJWH.S142078
  23. Bitzer J. Hormone withdrawal-associated symptoms: overlooked and under-explored. Gynecol Endocrinol 2013; 29 (6): 530–5. doi: 10.3109/09513590.2012.760194
  24. Baerwald AR, Pierson RA. Ovarian follicular development during the use of oral contraception: a review. J Obstet Gynaecol Can 2004; 26: 19–24.
  25. Sullivan H, Furniss H, Spona J et al. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity. Fertil Steril 1999; 72:115–20.
  26. Klipping C, Duijkers I, Trummer D et al. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception 2008; 78: 16–25.
  27. Spona J, Elstein M, Feichtinger W et al. Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception 1996; 54: 71–7.
  28. Legro RS, Pauli JG, Kunselman AR et al. Effects of continuous versus cyclical oral contraception: a randomized controlled trial. J Clin Endocrinol Metab 2008;93: 420–9.
  29. Zeun S et al. Pharmacokinetics of an oral contraceptive containing oestradiol valerate and dienogest. Eur J Contracept Reprod Health Care 2009; 14: 221–32.
  30. Fruzzetti F et al. An overview of the development of combined oral contraceptives containing estradiol: focus on estradiol valerate/dienogest. Gynecol Endocrinol 2012; 28: 400–8.
  31. Endrikat J, Blode H, Gerlinger C et al. A pharmacokinetic study with a low-dose oral contraceptive containing 20 microg ethinylestradiol plus 100 microg levonorgestrel. Eur J Contracept Reprod Health Care 2002; 7: 79–90.
  32. MacGregor EA, Guillebaud J. The 7-day contraceptive hormone-free interval should be consigned to history. BMJ Sexual & Reproductive Health 2018. doi: 10.1136/bmjsrh-2017-200036
  33. Machado RB, Pereira AP, Coelho GP et al. Epidemiological and clinical aspects of migraine in users of combined oral contraceptives. Contraception 2010; 81 (3): 202–8. doi: 10.1016/j.contraception.2009.09.006
  34. Merki-Feld GS et al. Temporal relations in hormone-withdrawal migraines and impact on prevention- a diary-based pilot study in combined hormonal contraceptive users. J Headache Pain 2017; 18 (1): 91. doi: 10.1186/s10194-017-0801-7
  35. Cupini LM, Matteis M, Troisi E et al. Sex-hormone-related events in migrainous females. A clinical comparative study between migraine with aura and migraine without aura. Cephalalgia 1995; 15: 140–4.
  36. Sacco S, Merki-Feld GS et al. Effect of exogenous estrogens and progestogens on the course of migraine during reproductive age: a consensus statement by the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESCRH). J Headache Pain 2018; 19 (1): 76. doi: 10.1186/s10194-018-0896-5
  37. De Icco R et al. Modulation of nociceptive threshold by combined hormonal contraceptives in women with oestrogen-withdrawal migraine attacks: a pilot study. J Headache Pain 2016; 17 (1): 70. doi: 10.1186/s10194-016-0661-6
  38. Macìas G, Merki-Feld GS, Parke S et al. Effects of a combined oral contraceptive containing oestradiol valerate/dienogest on hormone withdrawal-associated symptoms: results from the multicentre, randomised, double-blind, active-controlled HARMONY II study. J Obstet Gynaecol 2013; 33 (6): 591–6. doi: 10.3109/01443615.2013.800851
  39. Nappi RE, Terreno E, Sances G et al. Effect of a contraceptive pill containing estradiol valerate and dienogest (E2V/DNG) in women with menstrually-related migraine (MRM). Contraception 2013; 88 (3): 369–75. doi: 10.1016/j.contraception.2013.02.001.
  40. Graziottin A, Serafini A. Perimenstrual asthma: from pathophysiology to treatment strategies. Multidiscip Respir Med 2016; 11: 30. doi: 10.1186/s40248-016-0065-0
  41. Микаелян С.Т. Половые гормоны и бронхиальная астма у женщин. Успехи современного естествознания. 2007; 6: 76–8. [Mikaelian S.T. Polovye gormony i bronkhial’naia astma u zhenshchin. Uspekhi sovremennogo estestvoznaniia. 2007; 6: 76–8 (in Russian).]
  42. Овчаренко С.И., Капустина В.А. Особенности хронической обструктивной болезни легких у женщин. Consilium Medicum. 2009; 3: 5–13. [Ovcharenko S.I., Kapustina V.A. Osobennosti khronicheskoi obstruktivnoi bolezni legkikh u zhenshchin. Consilium Medicum. 2009; 3: 5–13 (in Russian).]
  43. Андреева Е.Н., Шереметьева Е.В. Проблема женской сексуальности. Проблемы репродукции. 2019; 25 (3): 40–50. [Andreeva E.N., Sheremet’eva E.V. Problema zhenskoi seksual’nosti. Problemy reproduktsii. 2019; 25 (3): 40–50. (in Russian).]
  44. Borgelt LM, Martell CW. Estradiol Valerate/Dienogest: A Novel Combined Oral Contraceptive. Clin Ther 2012; 34 (1): 37–55. doi: 10.1016/j.clinthera.2011.11.006
  45. Briggs P, Serrani M, Vogtländer K, Parke S. Continuation rates, bleeding profile acceptability, and satisfaction of women using an oral contraceptive pill containing estradiol valerate and dienogest versus a progestogen-only pill after switching from an ethinylestradiol-containing pill in a real-life setting: results of the CONTENT study. Int J Womens Health 2016; 8: 477–87.
  46. Jensen JT, Bitzer J, Nappi RE et al. Pooled analysis of bleeding profile, efficacy and safety of oral oestradiol valerate/dienogest in women aged 25 and under. Eur J Contracept Reprod Health Care 2020; 25 (2): 98–105. doi: 10.1080/13625187.2020.1731734
  47. Dinger J, Do Minh T, Heinemann K. Impact of estrogen type on cardiovascular safety of combined oral contraceptives. Contraception 2016; 94: 328–39.



Abstract - 63

PDF (Russian) - 33





  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies